Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Intervention Development

NCT04077138
View directory record Official record
Conditions
HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions
Not listed
Lead sponsor
Hektoen Institute for Medical Research
Other
Eligibility
15 Years to 24 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

NCT03110380
View directory record Official record
Conditions
HIV-1-infection
Interventions
B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
66
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Results available

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

NCT02985996
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Genvoya
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

NCT00076791
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

NCT03512418
View directory record Official record
Conditions
HIV Infections, Substance Use Disorders
Interventions
PrEPsteps, Digital pill, Truvada
Behavioral · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boylston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet

NCT01694420
View directory record Official record
Conditions
HIV
Interventions
(FDC) ELV/COBI/FTC/TDF
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

NCT00414518
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 2 Interventional

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

NCT00036452
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
27
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107
View directory record Official record
Conditions
HIV-1 Infection
Interventions
RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
63
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis in YMSM

NCT01033942
View directory record Official record
Conditions
HIV
Interventions
coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP, Placebo, Many Men, Many Voices (3MV)
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 22 Years · Male only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

NCT04692077
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, CAB LA, Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

NCT01721109
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
EVG/COBI/FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Oakland, California • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

NCT00737568
View directory record Official record
Conditions
Hepatitis B
Interventions
TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 4 Interventional

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

NCT02220868
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Sofosbuvir, Ribavirin, and Stribild
Drug
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 13, 2026, 6:11 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

NCT03255915
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC), Placebo
Drug · Other
Lead sponsor
Oak Crest Institute of Science
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 6:11 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

NCT06101342
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

NCT01102972
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Reyataz + Norvir + Truvada, Reyataz + Epzicom
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
44
States / cities
Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

NCT02276612
View directory record Official record
Conditions
HIV
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Tampa, Florida • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

NCT03048422
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01797445
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 13, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men

NCT03771638
View directory record Official record
Conditions
Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis, HIV Prevention
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app
Drug · Other
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 13, 2026, 6:11 PM EDT